Related Experiment Videos
PCL microparticle-dispersed PLGA solution as a potential injectable urethral bulking agent
Se Heang Oh1, Ji Youl Lee, Sung Ho Ghil
1Department of Polymer Science and Engineering, Hannam University, 133 Ojeong Dong, Daedeog Gu, Daejeon 306-791, Republic of Korea.
Biomaterials
|October 14, 2005
Summary
Injectable poly(d,l-lactic-co-glycolic acid) (PLGA) solutions with polycaprolactone (PCL) microparticles show promise for treating urinary incontinence. This biocompatible bulking agent offers excellent injectability and sustained volume retention.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Urology
Background:
- Urinary incontinence affects millions globally, necessitating effective and minimally invasive treatment options.
- Current injectable bulking agents often suffer from poor volume retention and migration issues.
- Developing biocompatible materials with stable in-vivo performance is crucial for improving patient outcomes.
Purpose of the Study:
- To develop and evaluate a novel injectable bulking agent for urethral applications using polycaprolactone (PCL) microparticles dispersed in a poly(dl-lactic-co-glycolic acid) (PLGA) solution.
- To assess the injectability, volume retention, biocompatibility, and tissue integration of the PCL-PLGA composite material.
- To determine the potential of this formulation as a treatment for stress urinary incontinence.
Main Methods:
- Polycaprolactone (PCL) microparticles were fabricated using a temperature-induced phase transition method.
- PCL microparticles were dispersed in a 10wt% poly(dl-lactic-co-glycolic acid) (PLGA) solution in tetraglycol at varying ratios.
- The mixture was injected subcutaneously into hairless mice, and its properties were evaluated over 8 weeks, including injectability, volume stability, and inflammatory response.
Main Results:
- The PCL microparticle-dispersed PLGA solution demonstrated excellent injectability through an 18G needle.
- Upon contact with water, a stable, porous PLGA matrix formed, entrapping PCL microparticles and preventing migration.
- The formulation showed sustained volume retention and minimal inflammatory response in vivo, with gradual tissue infiltration up to 8 weeks.
Conclusions:
- The PCL microparticle-dispersed PLGA solution exhibits favorable injectability, volume retention, and biocompatibility, making it a promising candidate for urethral bulking.
- This novel biomaterial addresses key limitations of existing bulking agents, offering potential for improved treatment of urinary incontinence.
- Further studies are warranted to confirm its efficacy and safety in clinical settings for treating urinary incontinence.